Novo Nordisk and Echosens partner up to develop diagnostics for "silent disease"
NASH, a metabolic liver disease, has no early stage symptoms, and people therefore go undiagnosed, which the two firms are now seeking to change.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
NASH, or non-alcoholic steatohepatitis, is a focus area of Danish pharmaceutical giant Novo Nordisk – however, the disease’s nature poses a particular problem when it comes to treatment as it often goes undiagnosed until it is too late.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk and Gilead expand partnership
For subscribers
